• UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase3 ACHIEVEI and ACHIEVEII studies.
• CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults.
• Migraine affects an estimated 5million Canadians with the highest prevalence in women and individuals in their 30s and 40s.

MONTREAL, Aug. 4, 2026 /CNW/ -- AbbVie (NYSE:ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with moderate to severe pain.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.